Bringing precision medicine to cancer care in Queensland


Cancer affects 1 in 2 males and 1 in 3 females in Queensland throughout their lifetimes.

Emerging technologies and genomics research is revolutionising how cancer is diagnosed, treated and prevented. Advances in precision medicine through genome sequencing and analysis of patient tumours has allowed scientists to identify genetic changes associated with specific cancers.

This new knowledge is improving patient care and saving lives by allowing doctors to undertake tailored treatment strategies for patients. As well as individual project outcomes, the Cancer Portfolio Projects will work together to establish key infrastructure to support the clinical delivery of cancer genomics in Queensland by:

  • Establishing statewide governance and a cancer genomics advisory service to support the adoption of genomics within Queensland cancer services

  • Considerations for Queensland’s integrated electronic Medical Record

The following cancer genomics projects are part of Queensland Genomics’ Round 2 Cancer Portfolio.

 
 

Queensland myeloid genomics program - improving the survival of children and adults with myeloid cancers

Acute myeloid cancers affect the blood and bone marrow, with approximately 900 Australians diagnosed each year. This type of cancer progresses rapidly and is usually fatal within weeks or months without treatment. This project will use genomic testing to improve the diagnosis, prognosis and therapy options for patients with myeloid cancers.

Myeloid blood cancers are difficult to treat with patients often requiring a bone marrow transplant to increase their chance of survival. Bone marrow transplantation is a complicated procedure with significant risks and long recovery times. Precise prognostic data provided through genomic testing will improve treatment pathways and decisions for bone marrow transplant services for Queensland patients.

This is a clinical implementation project, which applies best evidence to clinical practice and is intended to become standard of care following completion of the project.

PROJECT LEAD: Dr Cameron Curley (Royal Brisbane & Women’s Hospital)

 

Q-IMPROvE implimentation of precision oncology in breast cancer

Breast cancer is a heterogeneous disease, making it difficult for doctors to predict whether or not standard treatments, such as chemotherapy, will provide any benefit to an individual patient. This project will use genomics to further implement precision medicine for breast cancer patients in Queensland. Whole genome sequencing will identify the unique profile of an individual’s tumour.

The resulting data will allow clinicians to predict which patients are more likely to respond well to specific cancer treatments, tailoring each patient’s treatment plan to target genetic abnormalities of their specific cancer.

This is a clinical innovation project, which explores new applications of medical genomics in clinical practice.

PROJECT LEAD: Professor Sunil Lakhani (The University of Queensland; Pathology Queensland)